178 related articles for article (PubMed ID: 24150821)
21. Impact of off-label use regulations on patient care in dermatology - a prospective study of cost-coverage applications filed by tertiary dermatology clinics throughout Germany.
Werner RN; Pennitz A; Eisert L; Schmidle P; Zink A; Abraham S; Schäkel K; Wolff I; Goebeler M; Plange J; Sollfrank L; Zielbauer S; Koll P; Amschler K; Müller V; Nast A
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2241-2249. PubMed ID: 35737866
[TBL] [Abstract][Full Text] [Related]
22. Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey.
Palčevski G; Skočibušić N; Vlahović-Palčevski V
Eur J Clin Pharmacol; 2012 Jul; 68(7):1073-7. PubMed ID: 22307225
[TBL] [Abstract][Full Text] [Related]
23. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].
Janzen RW; Ludwig WD;
Z Rheumatol; 2012 Feb; 71(2):108-10, 112-8. PubMed ID: 22370801
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacotherapy of atopic eczema--an analysis of the discrepancies between recent expert guidelines, official drug licenses, and evidence for efficacy of recommended drugs].
Kordus K; Spiewak R
Przegl Lek; 2013; 70(12):1021-6. PubMed ID: 24720120
[TBL] [Abstract][Full Text] [Related]
25. Off-label use of medicine in pediatrics: focus on gastrointestinal diseases.
Karesh A; Tomaino J; Mulberg AE
Curr Opin Pediatr; 2013 Oct; 25(5):612-7. PubMed ID: 23995427
[TBL] [Abstract][Full Text] [Related]
26. [Off-label therapy in rheumatology].
Krüger K; Sieper J
Z Rheumatol; 2012 Feb; 71(2):99-100. PubMed ID: 22370799
[No Abstract] [Full Text] [Related]
27. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature.
Lindell-Osuagwu L; Korhonen MJ; Saano S; Helin-Tanninen M; Naaranlahti T; Kokki H
J Clin Pharm Ther; 2009 Jun; 34(3):277-87. PubMed ID: 19650250
[TBL] [Abstract][Full Text] [Related]
28. Regulating off-label promotion of medications: has the pendulum swung too far?
Hoffman MB; Yentzer BA; Feldman SR
Skin Therapy Lett; 2015; 20(3):1-4. PubMed ID: 26382556
[TBL] [Abstract][Full Text] [Related]
29. A clinical audit of high-cost and off-label drug use in dermatology.
Ong N; McMeniman E; Pillans P; Soyer HP
Australas J Dermatol; 2017 Feb; 58(1):30-34. PubMed ID: 26344939
[TBL] [Abstract][Full Text] [Related]
30. [Medicines for children and "off-label use" 5 years after implementation of the Paediatric Regulation (EC) No 1901/2006. An interim analyis].
Afentaki A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Sep; 57(9):1111-9. PubMed ID: 25139386
[TBL] [Abstract][Full Text] [Related]
31. Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies.
França K; Litewka S
Int J Dermatol; 2019 Jul; 58(7):788-794. PubMed ID: 30168846
[TBL] [Abstract][Full Text] [Related]
32. [Research Status on Off-label Use in Appraisal for Medical Malpractice].
Leng BN; Wang X
Fa Yi Xue Za Zhi; 2018 Apr; 34(2):171-174. PubMed ID: 29923385
[TBL] [Abstract][Full Text] [Related]
33. Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Guenther L; Lynde C; Poulin Y
J Cutan Med Surg; 2019; 23(4_suppl):27S-34S. PubMed ID: 31476936
[TBL] [Abstract][Full Text] [Related]
34. Off-label prescribing in the treatment of dermatologic disease.
Sugarman JH; Fleischer AB; Feldman SR
J Am Acad Dermatol; 2002 Aug; 47(2):217-23. PubMed ID: 12140467
[TBL] [Abstract][Full Text] [Related]
35. Licensing and labelling of drugs in a paediatric oncology ward.
van den Berg H; Tak N
Br J Clin Pharmacol; 2011 Sep; 72(3):474-81. PubMed ID: 21453298
[TBL] [Abstract][Full Text] [Related]
36. [Solutions for off-label therapy].
Schmidt WA
Z Rheumatol; 2003; 62(Suppl 2):II54-6. PubMed ID: 14648094
[TBL] [Abstract][Full Text] [Related]
37. [G-DRG Version 2004: changes in view of dermatology].
Hensen P; Fürstenberg T; Irps S; Grabbe S; Schwarz T; Luger TA; Rompel R; Roeder N
J Dtsch Dermatol Ges; 2004 Jan; 2(1):15-23. PubMed ID: 16281878
[TBL] [Abstract][Full Text] [Related]
38. [Physician versus 'off-label" ordinance].
Kordus K; Spiewak R
Przegl Lek; 2015; 72(1):38-41. PubMed ID: 26076577
[TBL] [Abstract][Full Text] [Related]
39. Off-label drug use in human immunodeficiency virus disease.
Brosgart CL; Mitchell T; Charlebois E; Coleman R; Mehalko S; Young J; Abrams DI
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):56-62. PubMed ID: 8624761
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects.
Nagai S; Ozawa K
Invest New Drugs; 2016 Dec; 34(6):777-791. PubMed ID: 27538583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
